Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enterovirus A71 vaccine (inactivated)
- Development stage
- Unknown
- Lead developer
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This inactivated vaccine is designed to provide protection against Hand, Foot, and Mouth Disease (HFMD) caused by Enterovirus A71 (EV-A71). Developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) and licensed to Biovalys for the Thai market, the vaccine utilizes an inactivated form of the virus to stimulate the production of neutralizing antibodies. It is specifically indicated for the prevention of EV-A71 infection and the reduction of associated severe neurological complications, such as encephalitis and meningitis, which are primarily seen in infants and young children. The vaccine is administered via intramuscular injection and has been shown to be highly effective in clinical trials in preventing both mild and severe forms of the disease.
- Brand names
- Yi Er Kang
- Other names
- EV-A71 Vaccine (inactivated, developed by IMBCAMS)Enterovirus A71 VaccineIMBCAMS EV-A71 vaccine
Beyond the preview
Go deeper on enterovirus A71 vaccine (inactivated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enterovirus A71 vaccine (inactivated).